Treatment News : Giving Short-Term ARVs During Early HIV Infection Has Benefits

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Treatment News » January 2014

Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

20 Years Ago In POZ

More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to


January 8, 2014

Giving Short-Term ARVs During Early HIV Infection Has Benefits

Taking a relatively short course of antiretrovirals (ARVs) during primary, or early, HIV infection (PHI) provides immunological benefits for about a year after interrupting treatment, aidsmap reports. Publishing their findings in PLOS ONE, researchers conducted a meta-analysis of eight studies of treatment during PHI in which there was both a treatment and a control arm. The studies, which were published between 2004 and 2012, had cohorts ranging from 11 to 822 participants. They took ARVs for between 12 and 86 weeks and were then followed for between nine months and six years after the treatment interruption.

A year after stopping ARV treatment, those who underwent early treatment experienced an average increase of 86 CD4 cells and saw their viral load cut in half, as compared with the control group. Because those who received treatment tended to have lower CD4 counts and viral load measurements before starting treatment, the investigators assumed this quirk in the data biased the apparent benefits of early treatment as too low. After adjusting the results accordingly, they found that there was an even greater benefit to the early treatment.

Early treatment was the most beneficial to those who started out with lower CD4s and a higher viral load. Across the board, the benefits petered out after a year or two.

To read the aidsmap story, click here.

To read the study, click here.

Search: HIV, antiretrovirals, short-term therapy, aidsmap, PLOS ONE, treatment interruption, immunological benefit.

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Hide comments

Previous Comments:

  comments 1 - 1 (of 1 total)    

skeptical_in_dallas, Dallas, 2014-01-09 17:32:40
Doesn't this contradict the study results of the VISCONTI cohort? In that group viral load suppression was maintained even 6 years after stopping HAART.

comments 1 - 1 (of 1 total)    

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Did you participate in an event for National Black HIV/AIDS Awareness Day 2016?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.